Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 8OTHER 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Promyelocytic, Acute 1

Interventions

fludarabine 5Cyclophosphamide 5Azacitidine 4Cytarabine 3venetoclax 2pegylated granulocyte colony-stimulating factor 2bisantrene 2Metformin 2Etoposide 2Dasatinib 2Clofarabine 2Busulfan 2vosaroxin 1treosulfan 1peginterferon alfa-2a 1nilotinib 1liposomal amphotericin B 1fludarabine phosphate 1defactinib 1decitabine and cedazuridine drug combination 1cedazuridine 1cc-486 1aldesleukin 1Zinc Sulfate 1Zinc 1Vitamin D 1Urination 1Tranexamic Acid 1Thiotepa 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Lisaftoclax × Other hematologic neoplasm × Clear all
NCT07597941 2026-06-04

Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients

The Affiliated People's Hospital of Ningbo University

Phase 2/3 Not yet recruiting
60 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡